Table 1 Unadjusted outcomes at 3 years of acute myeloid leukemia (AML) patients with t(8;21) who achieved complete remission after 1–2 induction chemotherapy cycles
Group | CIR rate | LFS rate | OS rate |
|---|---|---|---|
Chemotherapy only | 71% (63%–80%) | 26% (15%–43%) | 41% (25%–58%) |
Auto-HSCT | 8% (0%–71%) | 85% (51%–96%) | 92% (57%–99%) |
Allo-HSCT | 16% (10%–22%) | 72% (56%–83%) | 77% (61%–87%) |
All cohorts | 37% (25%–50%) | 56% (45%–65%) | 65% (54%–74%) |